FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Heaney

Research Profile

Chemicals & Drugs

Living Beings

Mouse

Procedures

Physiology

Signal Transduction

Disorders

Concepts & Ideas

Anatomy

Co-author Network

Publications

TOP 3
Gabriela Soriano; Mark L Heaney
Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
Mark L Heaney
Saving orphans: BRAF targeting of histiocytosis.
John Mascarenhas; Vesna Najfeld; Bruce Petersen; Nikolai Podoltsev; Raajit Rampal; Farhad Ravandi; Gail Roboz; Martin Tallman; Omar Abdel-Wahab; Dan Douer; Eric Feldman; Mark L Heaney; Elizabeth Hexner; Ronald Hoffman; Ross Levine
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Heaney (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gabriela Soriano; Mark L Heaney
Polycythemia vera and essential thrombocythemia: new developments in biology with therapeutic implications.
Current opinion in hematology 2013;20(2):169-75.
2013: Mark L Heaney
Saving orphans: BRAF targeting of histiocytosis.
Blood 2013;121(9):1487-8.
2012: John Mascarenhas; Vesna Najfeld; Bruce Petersen; Nikolai Podoltsev; Raajit Rampal; Farhad Ravandi; Gail Roboz; Martin Tallman; Omar Abdel-Wahab; Dan Douer; Eric Feldman; Mark L Heaney; Elizabeth Hexner; Ronald Hoffman; Ross Levine
Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium.
Leukemia research 2012;36(12):1500-4.
2011: Renier J Brentjens; Marco L Davila; Mark Frattini; Elizabeth Halton; Mark L Heaney; Glenn Heller; Daniel Hollyman; James Hosey; Joseph G Jurcic; Peter Maslak; Malgorzata Olszewska; Jae H Park; Hollie Pegram; Domenick Pirraglia; Mark Przybylowski; Isabelle Riviere; Elmer Santos; David Scheinberg; Jolanta Stefanski; Clare Taylor; Yelena Usachenko; Xiuyan Wang; Raymond Yeh; Shirley Bartido; Yvette Bernal; Oriana Borquez-Ojeda; Michel Sadelain
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Blood 2011;118(18):4817-28.
2011: Jeffrey Crawford; Mark L Heaney; Sally Htoy; Susan Hudock; Dwight D Kloth; David J Kuter; Gary H Lyman; Brandon McMahon; David P Steensma; Saroj Vadhan-Raj; Peter Westervelt; Michael Westmoreland; Jeffrey Allen; James Armitage; Douglas W Blayney; Spero R Cataland
Myeloid growth factors.
Journal of the National Comprehensive Cancer Network : JNCCN 2011;9(8):914-32.
2011: Prabodhika R Mallikaratchy; Alessandro Ruggiero; Jeffrey R Gardner; Vitaly Kuryavyi; William F Maguire; Mark L Heaney; Michael R McDevitt; Dinshaw J Patel; David A Scheinberg
A multivalent DNA aptamer specific for the B-cell receptor on human lymphoma and leukemia.
Nucleic acids research 2011;39(6):2458-69.
2010: Todd Rosenblat; Michael R McDevitt; Deborah A Mulford; Neeta Pandit-Taskar; Chaitanya R Divgi; Katherine S Panageas; Mark L Heaney; Suzanne Chanel; Alfred Morgenstern; George Sgouros; Steven M Larson; David A Scheinberg; Joseph G Jurcic
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(21):5303-11.
2010: Sindy Escobar-Alvarez; Jeffrey Gardner; Aneesh Sheth; Giovanni Manfredi; Guangli Yang; Ouathek Ouerfelli; Mark L Heaney; David A Scheinberg
Inhibition of human peptide deformylase disrupts mitochondrial function.
Molecular and cellular biology 2010;30(21):5099-109.
2010: Priya Koppikar; Omar Abdel-Wahab; Cyrus V Hedvat; Sachie Marubayashi; Jay Patel; Aviva Goel; Nicole Kucine; Jeffrey R Gardner; Andrew P Combs; Kris Vaddi; Patrick J Haley; Timothy C Burn; Mark Rupar; Jacqueline F Bromberg; Mark L Heaney; Elisa de Stanchina; Jordan S Fridman; Ross Levine
Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Blood 2010;115(14):2919-27.
2009: Mark L Heaney; Edmond L Toy; Francis Vekeman; François Laliberté; Bree L Dority; Daniel Perlman; Victoria Barghout; Mei Sheng Duh
Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
Cancer 2009;115(20):4839-48.
2009: Nicole Lamanna; Joseph G Jurcic; Ariela Noy; Peter Maslak; Alison Gencarelli; Katherine S Panageas; Mark L Heaney; Renier J Brentjens; David W Golde; David A Scheinberg; Andrew D Zelenetz; Mark A Weiss
Sequential therapy with fludarabine, high-dose cyclophosphamide, and rituximab in previously untreated patients with chronic lymphocytic leukemia produces high-quality responses: molecular remissions predict for durable complete responses.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(4):491-7.
2009: Jeffrey Crawford; James Armitage; Lodovico Balducci; Charles L Bennett; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; Harry P Erba; James Foran; Alison G Freifeld; Marti Goemann; Mark L Heaney; Sally Htoy; Susan Hudock; Dwight D Kloth; David J Kuter; Gary H Lyman; Laura Boehnke Michaud; Sarah C Miyata; Martin S Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K Wong
Myeloid growth factors.
Journal of the National Comprehensive Cancer Network : JNCCN 2009;7(1):64-83.
2008: Mark L Heaney; Jeffrey R Gardner; Nicos Karasavvas; David W Golde; David A Scheinberg; Emily A Smith; Owen A O'Connor
Vitamin C antagonizes the cytotoxic effects of antineoplastic drugs.
Cancer research 2008;68(19):8031-8.
2008: Luca Paoluzzi; Mithat Gonen; Govind Bhagat; Richard R Furman; Jeffrey R Gardner; Luigi Scotto; Volodia D Gueorguiev; Mark L Heaney; Katia Manova-Todorova; Owen A O'Connor
The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.
Blood 2008;112(7):2906-16.
2008: Luca Paoluzzi; Mithat Gonen; Jeffrey R Gardner; Jill Mastrella; Dajun Yang; Jon Holmlund; Mel Sorensen; Lance Leopold; Katia Manova-Todorova; Guido Marcucci; Mark L Heaney; Owen A O'Connor
Targeting Bcl-2 family members with the BH3 mimetic AT-101 markedly enhances the therapeutic effects of chemotherapeutic agents in in vitro and in vivo models of B-cell lymphoma.
Blood 2008;111(11):5350-8.
2008: Ross Levine; Mark L Heaney
New advances in the pathogenesis and therapy of essential thrombocythemia.
Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2008;():76-82.
2008: Sanjay Mandal; Steven Q Wang; Klaus J Busam; Mark L Heaney; Liang Deng
Multiple erythematous eroded patches and papules on the scalp.
Archives of dermatology 2008;144(1):105-10.
2007: Jeffrey Crawford; Betsy Althaus; James Armitage; Lodovico Balducci; Charles L Bennett; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; Harry P Erba; James Foran; Alison G Freifeld; Mark L Heaney; Sally Htoy; Dwight D Kloth; Gary H Lyman; Wells A Messersmith; Laura Boehnke Michaud; Sarah C Miyata; Amy Robbins; Martin S Tallman; Saroj Vadhan-Raj; Peter Westervelt; Michael K Wong
Myeloid growth factors. Clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2007;5(2):188-202.
2006: Daniel J DeAngelo; Richard M Stone; Mark L Heaney; Stephen D Nimer; Ronald L Paquette; Rebecca B Klisovic; Michael A Caligiuri; Michael R Cooper; Jean-Michel Lecerf; Michael D Karol; Shihong Sheng; Nick Holford; Peter T Curtin; Brian J Druker; Michael C Heinrich
Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamics.
Blood 2006;108(12):3674-81.
2006: Nicole Lamanna; Matt Kalaycio; Peter Maslak; Joseph G Jurcic; Mark L Heaney; Renier J Brentjens; Andrew D Zelenetz; Denise Horgan; Alison Gencarelli; Katherine S Panageas; David A Scheinberg; Mark A Weiss
Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(10):1575-81.
2006: Lorraine E Toner; Radovan Vrhovac; Emily A Smith; Jeffrey Gardner; Mark L Heaney; Mithat Gonen; Julie T Feldstein; Francis M Sirotnak; Owen A O'Connor
The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(3 Pt 1):924-32.
2006: Owen A O'Connor; Mark L Heaney; Lawrence H Schwartz; Stacie Richardson; Robert Willim; Barbara MacGregor-Cortelli; Tracey Curly; Craig Moskowitz; Carol S Portlock; Steven Horwitz; Andrew D Zelenetz; Stanley Frankel; Victoria M Richon; Paul Marks; W Kevin Kelly
Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(1):166-73.
2005: Jeffrey Crawford; Betsy Althaus; James Armitage; Douglas W Blayney; Spero R Cataland; David C Dale; George D Demetri; James Foran; Mark L Heaney; Sally Htoy; Dwight D Kloth; Gary H Lyman; Laura Boehnke Michaud; Susannah Motl; Saroj Vadhan-Raj; Michael K Wong
Myeloid growth factors clinical practice guidelines in oncology.
Journal of the National Comprehensive Cancer Network : JNCCN 2005;3(4):540-55.
2005: W Kevin Kelly; Owen A O'Connor; Lee M Krug; Judy H Chiao; Mark L Heaney; Tracy Curley; Barbara MacGregore-Cortelli; William Tong; J Paul Secrist; Lawrence H Schwartz; Stacie Richardson; Elaina Chu; Semra Olgac; Paul A Marks; Howard I Scher; Victoria M Richon
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(17):3923-31.
2004: Mona D Lee; Yuhong She; Michael J Soskis; Christopher P Borella; Jeffrey R Gardner; Paula A Hayes; Benzon M Dy; Mark L Heaney; Mark R Philips; William G Bornmann; Francis M Sirotnak; David A Scheinberg
Human mitochondrial peptide deformylase, a new anticancer target of actinonin-based antibiotics.
The Journal of clinical investigation 2004;114(8):1107-16.
2003: Timothy B Aliff; Peter Maslak; Joseph G Jurcic; Mark L Heaney; Kathleen N Cathcart; Kent A Sepkowitz; Mark A Weiss
Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin.
Cancer 2003;97(4):1025-32.
2002: John P Timoney; Mark G Malkin; D M Leone; Jeffrey S Groeger; Mark L Heaney; DL Keefe; M Klang; Charles D Lucarelli; Raymond J Muller; S L Eng; M Connor; Trudy N Small; Arthur E Brown; Leonard B Saltz
Safe and cost effective use of alteplase for the clearance of occluded central venous access devices.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(7):1918-22.
2002: W E Brown; Fergus V Coakley; Mark L Heaney
Renal involvement by Rosai-Dorfman disease: CT findings.
Abdominal imaging 2002;27(2):214-6.
2002: David W Golde; Andrzej J Jakubowiak; Janine Caggiano; Mark L Heaney
Cladribine underdosing in hairy-cell leukemia: a cause for apparent response failure.
Leukemia & lymphoma 2002;43(2):365-7.
2000: Mark L Heaney; Stephen D Nimer
Review of the Cox hematotoxicity model.
Journal of toxicology and environmental health. Part A 2000;61(5-6):539-41.
2000: J Tu; Nicos Karasavvas; Mark L Heaney; Juan Carlos C Vera; David W Golde
Molecular characterization of a granulocyte macrophage-colony-stimulating factor receptor alpha subunit-associated protein, GRAP.
Blood 2000;96(3):794-9.
2000: L Niu; Mark L Heaney; Juan Carlos C Vera; David W Golde
High-affinity binding to the GM-CSF receptor requires intact N-glycosylation sites in the extracellular domain of the beta subunit.
Blood 2000;95(11):3357-62.
2000: Mark L Heaney; David W Golde
Critical evaluation of the World Health Organization classification of myelodysplasia and acute myeloid leukemia.
Current oncology reports 2000;2(2):140-3.
1999: L Niu; David W Golde; Juan Carlos C Vera; Mark L Heaney
Kinetic resolution of two mechanisms for high-affinity granulocyte-macrophage colony-stimulating factor binding to its receptor.
Blood 1999;94(11):3748-53.
1999: Mark L Heaney; David W Golde
Myelodysplasia.
The New England journal of medicine 1999;340(21):1649-60.
1998: J Tu; David W Golde; Juan Carlos C Vera; Mark L Heaney
Expression of the human GM-CSF receptor alpha subunit in Saccharomyces cerevisiae.
Cytokines, cellular & molecular therapy 1998;4(3):147-51.
1998: Mark L Heaney; David W Golde
Soluble receptors in human disease.
Journal of leukocyte biology 1998;64(2):135-46.
1998: Coralia I Rivas; Juan Carlos C Vera; F Delgado-López; Mark L Heaney; Victor H Guaiquil; R H Zhang; Howard I Scher; Ilona I Concha; Francisco Nualart; Carlos Cordon-Cardo; David W Golde
Expression of granulocyte-macrophage colony-stimulating factor receptors in human prostate cancer.
Blood 1998;91(3):1037-43.
1996: Mark L Heaney; David W Golde
Soluble cytokine receptors.
Blood 1996;87(3):847-57.
1995: D X Ding; Juan Carlos C Vera; Mark L Heaney; David W Golde
N-glycosylation of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit is essential for ligand binding and signal transduction.
The Journal of biological chemistry 1995;270(41):24580-4.
1995: Mark L Heaney; Juan Carlos C Vera; M A Raines; David W Golde
Membrane-associated and soluble granulocyte/macrophage-colony-stimulating factor receptor alpha subunits are independently regulated in HL-60 cells.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(6):2365-9.
1995: C Spielholz; Mark L Heaney; M E Morrison; Alan N Houghton; Juan Carlos C Vera; David W Golde
Granulocyte-macrophage colony-stimulating factor signals for increased glucose uptake in human melanoma cells.
Blood 1995;85(4):973-80.
1994: D X Ding; Coralia I Rivas; Mark L Heaney; M A Raines; Juan Carlos C Vera; David W Golde
The alpha subunit of the human granulocyte-macrophage colony-stimulating factor receptor signals for glucose transport via a phosphorylation-independent pathway.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(7):2537-41.
1993: Mark L Heaney; D W Golde
Soluble hormone receptors.
Blood 1993;82(7):1945-8.
1987: Elizabeth J Taparowsky; Mark L Heaney; J T Parsons
Oncogene-mediated multistep transformation of C3H10T1/2 cells.
Cancer research 1987;47(15):4125-9.
1987: B J Biegalke; Mark L Heaney; A Bouton; Thomas J Parsons; M Linial
MC29 deletion mutants which fail to transform chicken macrophages are competent for transformation of quail macrophages.
Journal of virology 1987;61(7):2138-42.
1986: Mark L Heaney; J Pierce; Thomas J Parsons
Site-directed mutagenesis of the gag-myc gene of avian myelocytomatosis virus 29: biological activity and intracellular localization of structurally altered proteins.
Journal of virology 1986;60(1):167-76.